Fingerprint
Dive into the research topics of 'Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
Jeppe Romme Christensen, Rikke Ratzer, Lars Börnsen, Mark Lyksborg, Ellen Garde, Tim B Dyrby, Hartwig R Siebner, Per S Sorensen, Finn Sellebjerg